FI64952C - Foerfarande foer framstaellning av genetiskt stabila cellinjer - Google Patents
Foerfarande foer framstaellning av genetiskt stabila cellinjer Download PDFInfo
- Publication number
- FI64952C FI64952C FI781818A FI781818A FI64952C FI 64952 C FI64952 C FI 64952C FI 781818 A FI781818 A FI 781818A FI 781818 A FI781818 A FI 781818A FI 64952 C FI64952 C FI 64952C
- Authority
- FI
- Finland
- Prior art keywords
- cells
- antibody
- virus
- mouse
- antibodies
- Prior art date
Links
- 230000002068 genetic effect Effects 0.000 title 1
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims description 72
- 241000700605 Viruses Species 0.000 claims description 31
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 27
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 27
- 210000004989 spleen cell Anatomy 0.000 claims description 21
- 210000004754 hybrid cell Anatomy 0.000 claims description 20
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 claims description 18
- 241000711798 Rabies lyssavirus Species 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 230000003612 virological effect Effects 0.000 claims description 14
- 230000004927 fusion Effects 0.000 claims description 10
- 210000000628 antibody-producing cell Anatomy 0.000 claims description 8
- 241000712461 unidentified influenza virus Species 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 4
- 210000000952 spleen Anatomy 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 description 36
- 210000004408 hybridoma Anatomy 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 206010003445 Ascites Diseases 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 238000003127 radioimmunoassay Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 101710154606 Hemagglutinin Proteins 0.000 description 6
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 6
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 6
- 101710176177 Protein A56 Proteins 0.000 description 6
- 206010037742 Rabies Diseases 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 231100000263 cytotoxicity test Toxicity 0.000 description 6
- 239000000185 hemagglutinin Substances 0.000 description 6
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 241001494479 Pecora Species 0.000 description 3
- 241000473945 Theria <moth genus> Species 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- RJWUMFHQJJBBOD-UHFFFAOYSA-N 2-methylheptadecane Chemical compound CCCCCCCCCCCCCCCC(C)C RJWUMFHQJJBBOD-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 2
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 208000006678 Abdominal Neoplasms Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80685777A | 1977-06-15 | 1977-06-15 | |
| US80685777 | 1977-06-15 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI781818A7 FI781818A7 (fi) | 1978-12-16 |
| FI64952B FI64952B (fi) | 1983-10-31 |
| FI64952C true FI64952C (fi) | 1984-02-10 |
Family
ID=25194989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI781818A FI64952C (fi) | 1977-06-15 | 1978-06-07 | Foerfarande foer framstaellning av genetiskt stabila cellinjer |
Country Status (19)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2963410D1 (en) | 1978-08-10 | 1982-09-16 | Schering Ag | Process for obtaining murine immunglobulin-e antibodies, hybrid cell lines used in the process and the process for preparing them, application of the immunglobulin-e antibodies so obtained |
| CA1142466A (en) * | 1979-01-09 | 1983-03-08 | Cesar Milstein | Cell lines |
| US4271145A (en) * | 1979-10-22 | 1981-06-02 | The Massachusetts General Hospital | Process for producing antibodies to hepatitis virus and cell lines therefor |
| US5204095A (en) * | 1980-04-09 | 1993-04-20 | National Research Development Corporation | Monoclonal antibodies against hepatitis B virus |
| EP0038642B1 (en) * | 1980-04-09 | 1989-02-08 | National Research Development Corporation | A monoclonal antibody against hepatitis b and its production, a hybridoma producing the monoclonal antibody and compositions containing it, the propagation of the hybridoma and the monoclonal antibody for use as an antiviral agent against hepatitus b and in isolating hepatitus b surface antigen from a sample |
| NL185309C (nl) * | 1980-07-28 | 1990-03-01 | Akzo Nv | Methode voor het bepalen van antigenen met behulp van twee of meer monoklonale antilichamen alsmede immuunreagens. |
| JPS5825439B2 (ja) * | 1980-12-30 | 1983-05-27 | 株式会社林原生物化学研究所 | ヒト副甲状腺ホルモンの製造方法 |
| US4608337A (en) * | 1980-11-07 | 1986-08-26 | The Wistar Institute | Human hybridomas and the production of human monoclonal antibodies by human hybridomas |
| JPS609795B2 (ja) * | 1980-12-11 | 1985-03-13 | 株式会社林原生物化学研究所 | ヒト上皮細胞成長因子の製造方法 |
| JPS58500366A (ja) * | 1981-03-06 | 1983-03-10 | セルテツク リミテツド | 単一クロ−ン抗体 |
| AU567693B2 (en) * | 1982-09-30 | 1987-12-03 | University Of Rochester | Human monoclonal antibodies against bacterial toxins |
| JPH03271235A (ja) * | 1983-04-08 | 1991-12-03 | Kureha Chem Ind Co Ltd | 抗カンジダ菌抗体分泌ハイブリドーマ |
| JPS60104020A (ja) * | 1983-10-14 | 1985-06-08 | メルク エンド カムパニー インコーポレーテツド | Ａ型肝炎‐タンパク質サブユニツト抗原 |
| US4707442A (en) * | 1983-10-24 | 1987-11-17 | Board Of Regents, The University Of Texas System | Hybrid cell line producing monoclonal antibody cytolytic to Trichomonas vaginalis |
| US5053224A (en) * | 1983-11-07 | 1991-10-01 | Hilary Koprowski | Induction of antibody response to solid tumors with anti-idiotype antibodies |
| US4731237A (en) * | 1983-11-07 | 1988-03-15 | The Wistar Institute | Immune response to virus induced by anti-idiotype antibodies |
| NL8401221A (nl) * | 1984-04-16 | 1985-11-18 | Innovi Nv | Analytische toepassing van fagocyt-cellijnen. |
| JPS6140800A (ja) * | 1984-07-27 | 1986-02-27 | バイオテクノロジー アンド エクスペリメンタル リサーチ インコーポレーテツド | 電気細胞融合法を用いたモノクローナル抗体の製造方法 |
| JPS6181782A (ja) * | 1984-09-28 | 1986-04-25 | Teijin Ltd | 抗ウイルス・ヒト抗体を産生するマウス−ヒトハイブリド−マ及びその製造法並びにその使用方法 |
| EP0198086B1 (en) * | 1984-09-28 | 1991-01-16 | Teijin Limited | Mouse human hybridoma producing antivirus human antibody, process for its preparation, and antivirus human monoclonal antibody |
| JPS6226300A (ja) * | 1984-10-10 | 1987-02-04 | セントコ−・インコ−ポレ−テツド | Ｈｔｌｖ−３ｄｎａのクロ−ニングおよび発現 |
| GB8501473D0 (en) * | 1985-01-21 | 1985-02-20 | Pasteur Institut | Cloned dna sequences |
| JPS61104796A (ja) * | 1984-10-26 | 1986-05-23 | Chemo Sero Therapeut Res Inst | モノクロ−ナル抗体の製造方法 |
| JP2518607B2 (ja) * | 1985-08-29 | 1996-07-24 | 雪印乳業株式会社 | インフルエンザａ型ウイルスｈａ抗原に対するモノクロ―ナル抗体およびその作成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3423505A (en) * | 1964-10-31 | 1969-01-21 | Univ Toronto | Rabies vaccine and process for preparation thereof |
| US3585266A (en) * | 1969-02-24 | 1971-06-15 | Dow Chemical Co | Live rabies virus vaccine and method for the production thereof |
-
1978
- 1978-06-07 FI FI781818A patent/FI64952C/fi not_active IP Right Cessation
- 1978-06-07 ZA ZA00783261A patent/ZA783261B/xx unknown
- 1978-06-09 SE SE7806729A patent/SE7806729L/xx unknown
- 1978-06-12 FR FR7817545A patent/FR2394607A1/fr active Granted
- 1978-06-13 GB GB7826758A patent/GB2000186A/en not_active Withdrawn
- 1978-06-13 JP JP53071398A patent/JPS592276B2/ja not_active Expired
- 1978-06-13 ES ES470729A patent/ES470729A1/es not_active Expired
- 1978-06-14 AU AU37088/78A patent/AU525724B2/en not_active Expired
- 1978-06-14 CA CA305,453A patent/CA1103157A/en not_active Expired
- 1978-06-14 BE BE188549A patent/BE868099A/xx not_active IP Right Cessation
- 1978-06-14 DE DE19782826075 patent/DE2826075A1/de active Granted
- 1978-06-14 IT IT7824577A patent/IT1096742B/it active
- 1978-06-14 CH CH649278A patent/CH640735A5/de not_active IP Right Cessation
- 1978-06-14 NO NO782081A patent/NO782081L/no unknown
- 1978-06-14 IL IL54908A patent/IL54908A/xx unknown
- 1978-06-14 DK DK267378A patent/DK267378A/da not_active Application Discontinuation
- 1978-06-14 LU LU79812A patent/LU79812A1/de unknown
- 1978-06-15 PL PL20765278A patent/PL207652A1/xx unknown
- 1978-06-15 NL NL7806471A patent/NL7806471A/xx not_active Application Discontinuation
-
1982
- 1982-11-12 JP JP57198816A patent/JPS58101688A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IT1096742B (it) | 1985-08-26 |
| PL207652A1 (pl) | 1979-06-04 |
| IL54908A (en) | 1982-01-31 |
| AU3708878A (en) | 1979-12-20 |
| NO782081L (no) | 1978-12-15 |
| FR2394607A1 (fr) | 1979-01-12 |
| AU525724B2 (en) | 1982-11-25 |
| FI64952B (fi) | 1983-10-31 |
| CH640735A5 (de) | 1984-01-31 |
| JPS58101688A (ja) | 1983-06-16 |
| DE2826075A1 (de) | 1979-02-15 |
| DK267378A (da) | 1978-12-16 |
| FI781818A7 (fi) | 1978-12-16 |
| CA1103157A (en) | 1981-06-16 |
| ES470729A1 (es) | 1979-01-16 |
| IT7824577A0 (it) | 1978-06-14 |
| BE868099A (fr) | 1978-10-02 |
| FR2394607B1 (enrdf_load_stackoverflow) | 1983-12-30 |
| DE2826075C2 (enrdf_load_stackoverflow) | 1987-08-06 |
| SE7806729L (sv) | 1978-12-16 |
| ZA783261B (en) | 1979-06-27 |
| LU79812A1 (de) | 1978-12-07 |
| IL54908A0 (en) | 1978-08-31 |
| JPS5417185A (en) | 1979-02-08 |
| JPS592276B2 (ja) | 1984-01-18 |
| NL7806471A (nl) | 1978-12-19 |
| GB2000186A (en) | 1979-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI64952C (fi) | Foerfarande foer framstaellning av genetiskt stabila cellinjer | |
| US4196265A (en) | Method of producing antibodies | |
| Walsh et al. | Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein | |
| US4790987A (en) | Viral glycoprotein subunit vaccine | |
| JP3504661B2 (ja) | 呼吸器合胞体ウイルスに対するモノクローナルＩｇＡ抗体 | |
| Bruns et al. | Lymphocytic choriomeningitis virus. VI. Isolation of a glycoprotein mediating neutralization | |
| FI87734B (fi) | Immunologisk motverkan foer tumoerer och virus | |
| Mathews et al. | Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies | |
| EP0038642B1 (en) | A monoclonal antibody against hepatitis b and its production, a hybridoma producing the monoclonal antibody and compositions containing it, the propagation of the hybridoma and the monoclonal antibody for use as an antiviral agent against hepatitus b and in isolating hepatitus b surface antigen from a sample | |
| Tamura et al. | Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses | |
| DE69738312T2 (de) | Hepatitis b monoklonale antikörper | |
| CN111153988A (zh) | 广谱抗肠道病毒d68型的中和性单克隆抗体 | |
| PL172853B1 (pl) | Niezjadliwa szczepionka przeciw wsciekliznieoraz sposób wytwarzania niezjadliwej szczepionki przeciw wsciekliznie PL | |
| Smorodinsky et al. | Towards an idiotype vaccine against mammary tumors. Induction of an immune response to breast cancer‐associated antigens by anti‐idiotypic antibodies | |
| Stavrou et al. | Monoclonal antibodies reactive with glioma cell lines derived from experimental brain tumors | |
| FI111518B (fi) | Menetelmä monoklonaalisten vasta-aineiden ja vasta-ainetta sisältävän farmaseuttisen koostumuksen valmistamiseksi | |
| CN111450248B (zh) | 一种用于预防和治疗prrsv感染的抗体药物 | |
| Prabhakar et al. | Monoclonal antibody techniques applied to viruses | |
| Nagata et al. | Identification of epitopes associated with different biological activities on the glycoprotein of vesicular stomatitis virus by use of monoclonal antibodies | |
| CN111471104A (zh) | 一种prrsv广谱中和单克隆抗体及其应用 | |
| EP0370090B1 (en) | Immunogens and biologically active peptides derived from shared sequences from antigens and anti-idiotypic antibodies or antibodies specific for cellular receptors of the antigens | |
| Levings et al. | Generation by self re-fusion of bovine3× murine2 heterohybridomas secreting virus-neutralizing bovine monoclonal antibodies to bovine herpesvirus 1 glycoproteins gB, gC, and gD | |
| CN107446049B (zh) | 一种靶向人肝癌干细胞的单克隆抗体及其应用 | |
| Desgranges et al. | High affinity human monoclonal antibodies directed against hepatitis B surface antigen | |
| CN114773461B (zh) | 乙型脑炎病毒抗体1d11及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: THE WISTAR INSTITUTE |